PapersFlow Research Brief
Chemotherapy-induced organ toxicity mitigation
Research Guide
What is Chemotherapy-induced organ toxicity mitigation?
Chemotherapy-induced organ toxicity mitigation refers to strategies that counteract damage to organs such as the kidneys from drugs like cisplatin through mechanisms including antioxidants, modulation of oxidative stress, apoptosis, inflammation, and mitochondrial dysfunction.
Research encompasses 14,295 works on cisplatin-induced nephrotoxicity mechanisms and renoprotective interventions. Key areas include oxidative stress, apoptosis, inflammation, and mitochondrial dysfunction in kidney injury. "Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies" by Pabla and Dong (2008) details these processes and protective approaches with 1837 citations.
Topic Hierarchy
Research Sub-Topics
Cisplatin-Induced Oxidative Stress Nephrotoxicity
Researchers elucidate ROS generation, lipid peroxidation, and antioxidant enzyme depletion in proximal tubules from cisplatin. Studies test Nrf2 activators and radical scavengers for protection.
Apoptosis Pathways in Cisplatin Nephrotoxicity
This sub-topic maps intrinsic mitochondrial and extrinsic death receptor pathways activated by cisplatin-DNA adducts. Research evaluates Bcl-2 modulators and caspase inhibitors in preclinical models.
Inflammatory Mechanisms Cisplatin Kidney Injury
Studies investigate NF-κB activation, cytokine storms, and leukocyte infiltration contributing to cisplatin tubulointerstitial damage. Anti-inflammatory agents like dexamethasone are assessed clinically.
Mitochondrial Dysfunction Cisplatin Nephrotoxicity
Researchers probe cisplatin-induced mtDNA damage, electron transport chain inhibition, and fission-fusion imbalance in renal cells. Interventions target PGC-1α and mitophagy regulators.
Antioxidant Renoprotective Strategies Cisplatin
Clinical and preclinical trials evaluate N-acetylcysteine, amifostine, and novel NRF2 inducers for mitigating cisplatin nephrotoxicity. Dose-timing and biomarker-guided protocols are optimized.
Why It Matters
Mitigation strategies enable safer use of cisplatin in treating ovarian, testicular, lung, and bladder cancers, as noted in "The status of platinum anticancer drugs in the clinic and in clinical trials" by Wheate et al. (2010), where side effects limit dosing. "Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies" by Pabla and Dong (2008) identifies antioxidants and anti-inflammatory agents that preserve kidney function, allowing sustained therapy. In ovarian cancer trials, substituting carboplatin for cisplatin in "Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer" by Ozols et al. (2003) reduced toxicity while maintaining efficacy, with 2041 citations supporting its clinical adoption.
Reading Guide
Where to Start
"Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies" by Pabla and Dong (2008) provides a foundational overview of toxicity mechanisms and mitigation approaches, serving as an accessible entry with 1837 citations.
Key Papers Explained
"Cisplatin in cancer therapy: Molecular mechanisms of action" by Dasari and Tchounwou (2014, 5273 citations) explains cisplatin's DNA-targeting action, which Dasari and Florea and Büsselberg (2011, 1720 citations) extend to side effects like nephrotoxicity. Pabla and Dong (2008, 1837 citations) build on this by detailing kidney mechanisms and strategies, while Nezu et al. (2017, 3445 citations) connects NRF2 antioxidative pathways as a targeted intervention. Calvert et al. (1989, 1874 citations) offers practical dosing to reduce toxicity.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current focus remains on NRF2 modulation from Nezu et al. (2017) and detailed mechanisms in Pabla and Dong (2008), with no recent preprints shifting priorities. Emphasis persists on antioxidants and inflammation blockers for cisplatin kidney protection.
Papers at a Glance
Frequently Asked Questions
What are the main mechanisms of cisplatin nephrotoxicity?
Cisplatin induces kidney damage via oxidative stress, apoptosis, inflammation, and mitochondrial dysfunction. "Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies" by Pabla and Dong (2008) outlines these pathways. Interventions target these to protect renal cells.
How does the KEAP1-NRF2 system mitigate kidney toxicity?
NRF2 activates antioxidative genes to counter oxidative stress in kidney disease. "Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression" by Nezu et al. (2017) shows KEAP1 regulates NRF2 for cytoprotection. This system offers renoprotective potential against cisplatin.
What renoprotective strategies exist for cisplatin?
Strategies include antioxidants and modulation of inflammatory pathways. "Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies" by Pabla and Dong (2008) reviews approaches to block apoptosis and mitochondrial damage. These preserve glomerular filtration during therapy.
Why is carboplatin preferred over cisplatin in some cases?
Carboplatin dosing uses a formula based on glomerular filtration rate to minimize nephrotoxicity. "Carboplatin dosage: prospective evaluation of a simple formula based on renal function" by Calvert et al. (1989) derived this with r=0.85 correlation to clearance. Ozols et al. (2003) confirmed reduced toxicity in ovarian cancer.
What side effects do platinum drugs cause?
Platinum drugs like cisplatin cause seven side effects including nephrotoxicity. "The side effects of platinum-based chemotherapy drugs: a review for chemists" by Oun et al. (2018) lists these impacts. Mitigation focuses on kidney protection.
How does cisplatin exert anti-tumor effects?
Cisplatin induces tumor cell death via DNA damage and replication interference. "Cisplatin in cancer therapy: Molecular mechanisms of action" by Dasari and Tchounwou (2014) details these with 5273 citations. Off-target organ toxicity requires mitigation.
Open Research Questions
- ? How can NRF2 activation specifically block cisplatin-induced mitochondrial dysfunction in renal cells?
- ? What novel antioxidants outperform existing ones in preventing cisplatin nephrotoxicity without reducing anti-tumor efficacy?
- ? Which inflammatory pathways dominate cisplatin kidney injury, and how do targeted inhibitors preserve glomerular function?
- ? Can dosage formulas like Calvert's be refined to further minimize nephrotoxicity across patient GFR ranges?
- ? How do cellular resistance mechanisms to cisplatin in tumors differ from those in kidney cells?
Recent Trends
The field holds steady at 14,295 works with no 5-year growth data available and no recent preprints or news in the last 12 months.
High-impact papers like Nezu et al. (2017, 3445 citations) on NRF2 and Pabla and Dong (2008, 1837 citations) continue to guide renoprotective research.
Research Chemotherapy-induced organ toxicity mitigation with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Chemotherapy-induced organ toxicity mitigation with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers